|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
7
|
|
pubmed:dateCreated |
2006-8-30
|
|
pubmed:abstractText |
During the past decade, liposomal amphotericin B has been used with increasing frequency to treat visceral leishmaniasis (VL). The World Health Organization convened a workshop to review current knowledge and to develop guidelines for liposomal amphotericin B use for VL. In Europe, liposomal amphotericin B is widely used to treat VL. In Africa and Asia, the VL disease burden is high and drug access is poor; liposomal amphotericin B is available only through preferential pricing for nonprofit groups in East Africa. Clinical trials and experience demonstrate high efficacy and low toxicity for liposomal amphotericin B (total dose, 20 mg/kg) in immunocompetent patients with VL. Combination trials in areas with antileishmanial drug resistance, and treatment and secondary prophylaxis trials in VL-human immunodeficiency virus-coinfected patients, are important to safeguard the current armamentarium and to optimize regimens. The public health community should work to broaden access to preferential liposomal amphotericin B pricing by public sector VL treatment programs.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Oct
|
|
pubmed:issn |
1537-6591
|
|
pubmed:author |
pubmed-author:Adler-MooreJillJ,
pubmed-author:AlvarJorgeJ,
pubmed-author:BerenguerJuanJ,
pubmed-author:BernCarynC,
pubmed-author:BoelaertMarleenM,
pubmed-author:DavidsonRobert NRN,
pubmed-author:FiguerasConcepcionC,
pubmed-author:GradoniLuigiL,
pubmed-author:KafetzisDimitris ADA,
pubmed-author:RitmeijerKoertK,
pubmed-author:RosenthalEricE,
pubmed-author:RoyceCatherineC,
pubmed-author:RussoRosarioR,
pubmed-author:SundarShyamS,
pubmed-author:den BoerMargrietM
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
1
|
|
pubmed:volume |
43
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
917-24
|
|
pubmed:dateRevised |
2008-9-25
|
|
pubmed:meshHeading |
pubmed-meshheading:16941377-AIDS-Related Opportunistic Infections,
pubmed-meshheading:16941377-Amphotericin B,
pubmed-meshheading:16941377-Animals,
pubmed-meshheading:16941377-Antiprotozoal Agents,
pubmed-meshheading:16941377-Clinical Trials as Topic,
pubmed-meshheading:16941377-Drug Carriers,
pubmed-meshheading:16941377-Drug Costs,
pubmed-meshheading:16941377-Health Planning Guidelines,
pubmed-meshheading:16941377-Humans,
pubmed-meshheading:16941377-Leishmaniasis, Visceral,
pubmed-meshheading:16941377-Liposomes,
pubmed-meshheading:16941377-Treatment Outcome
|
|
pubmed:year |
2006
|
|
pubmed:articleTitle |
Liposomal amphotericin B for the treatment of visceral leishmaniasis.
|
|
pubmed:affiliation |
Division of Parasitic Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
